Etravirine
A second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for treatment of HIV-1 infection.HIV Infection Approved (In Vitro) :TMC125 is highly active against wild-type HIV-1 (50% effective concentration [EC50]=1.4 to 4.8 nM) and shows some activity against HIV-2 (EC50=3.5 μM) . TMC125 also inhibits a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. TMC125 has activity for 19 viruses with EC50 of < 5 nM. (In Vivo) :Etravirine has a high genetic barrier to the development of resistance. In phase IIb trials in treatment-experienced patients, including those infected with virus resistant to NNRTIs and protease inhibitors (PIs), TMC125 is active against HIV resistant to currently available NNRTIs, with a similar tolerability profile to that of the control group.
Product Specifications
CAS Number
269055-15-4
Product Name Alternative
R-165335 | TMC-125
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
N#CC1=CC (C) =C (OC2=NC (NC3=CC=C (C#N) C=C3) =NC (N) =C2Br) C (C) =C1
Molecular Formula
C20H15BrN6O
Molecular Weight
435.2767
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzonitrile, 4-[[6-amino-5-bromo-2-[ (4-cyanophenyl) amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD8 (CD 8, CD8 Antigen alpha Polypeptide, Leu2 T Lymphocyte Antigen, MAL, OKT8 T Cell Antigen, p32, T Cell Antigen Leu2, T Cell Surface Glycoprotein CD8 alpha Chain) (HRP)
CD8 (CD 8, CD8 Antigen alpha Polypeptide, Leu2 T Lymphocyte Antigen, MAL, OKT8 T Cell Antigen, p32, T Cell Antigen Leu2, T Cell Surface Glycoprotein CD8 alpha Chain) (HRP)
